Alprostadil (Caverject/MUSE) Metabolism and Energy Expenditure

What Alprostadil Is and Why Its Metabolism Matters

Alprostadil is synthetic prostaglandin E1 (PGE1). Its metabolic fate is clinically relevant for two reasons: first, it determines how much drug reaches systemic circulation and whether systemic cardiovascular or metabolic effects occur; second, the local enzymatic activity driving its degradation is the same machinery that governs eicosanoid signaling in vascular and adipose tissue.

In the Linet et al. Trial published in the New England Journal of Medicine (N=683, 1996), intracavernosal alprostadil produced satisfactory erections in approximately 70% of men with PDE5-inhibitor-refractory erectile dysfunction [1]. That efficacy record has kept alprostadil on first-line formularies for refractory ED for nearly three decades. Understanding the pharmacokinetics behind that record also explains why systemic side effects are rare at standard doses.

Prostaglandin E1 as a Vasoactive Eicosanoid

Alprostadil belongs to the eicosanoid class. Eicosanoids are 20-carbon, lipid-derived signaling molecules synthesized from arachidonic acid via cyclooxygenase (COX) pathways. PGE1 differs structurally from the more abundant endogenous prostaglandin E2 (PGE2) by a single double bond; that small difference shifts receptor selectivity, metabolic stability, and downstream cAMP production enough to produce clinically distinct effects [2].

Prostaglandin receptors EP1 through EP4 mediate PGE1 activity. EP2 and EP4 are Gs-coupled, meaning they raise intracellular cyclic AMP (cAMP). In corporal smooth muscle, elevated cAMP activates protein kinase A, which phosphorylates myosin light-chain kinase and opens potassium and calcium channels, producing relaxation and penile engorgement.

Why Rapid Metabolism Is the Design Goal

The lungs extract 68 to 80% of circulating PGE1 in a single pass [3]. This is not a side effect of poor drug design. It is a physiological safeguard that prevents a potent vasodilator from producing systemic hypotension after local administration. For clinicians, the practical consequence is that systemic hypotension after standard intracavernosal (IC) doses of 10 to 20 mcg is uncommon in otherwise healthy men. At doses above 40 mcg or in patients with severe hepatic or pulmonary disease, that margin narrows.

Absorption: Intracavernosal vs. Intraurethral Routes

The two approved delivery systems produce fundamentally different absorption profiles. Choosing between them is not merely a patient-preference decision; it is a pharmacokinetic one.

Intracavernosal Injection (Caverject, Edex)

After IC injection, alprostadil diffuses directly into corporal sinusoidal tissue. Local tissue concentrations in the corpus cavernosum rise within 2 to 5 minutes, producing smooth-muscle relaxation before any measurable systemic rise. A 1997 pharmacokinetic study by Wolfram et al. Found that peak plasma PGE1 concentrations after a 20 mcg IC dose reached only 2 to 4 pg/mL above baseline, a level insufficient to produce systemic vasodilatation in most patients [3].

Onset of erection is typically 5 to 20 minutes. Duration ranges from 30 to 60 minutes depending on dose and individual sensitivity. Because corporal tissue is highly vascularized, absorption into the systemic compartment is continuous but slow enough for pulmonary extraction to remain dominant.

Intraurethral Suppository (MUSE)

The MUSE system delivers alprostadil via a small pellet placed in the distal urethra. Absorption depends on urethral mucosal vascularity and the presence of residual urine, which dilutes the drug. Bioavailability via this route is substantially lower than IC injection. The corpus spongiosum and communicating venous channels carry drug into the corpora cavernosa, but peak cavernosal tissue levels reached with MUSE 1,000 mcg approximate only those from IC doses of 2 to 5 mcg [4].

The lower local concentration explains why MUSE tends to produce less rigid erections than equivalent-appearing IC doses. Urethral burning (reported in 11 to 32% of men in key trials) is directly attributable to high mucosal drug concentrations before systemic dilution occurs [4].

Topical and Compounded Formulations

Topical alprostadil cream (Vitaros, approved in Canada and the EU but not the U.S. As of this writing) applies drug to the glans penis. Transdermal absorption is low but measurable. Compounding pharmacies in the U.S. Prepare alprostadil in various topical bases; the FDA has not approved these formulations, and pharmacokinetic data are limited to small observational series.

Distribution and Protein Binding

Once absorbed into systemic circulation, alprostadil binds to plasma albumin with approximately 90% protein binding, a figure consistent with most lipophilic eicosanoids [3]. The volume of distribution for the parent compound is small because its half-life is so short that equilibration across tissue compartments is functionally irrelevant at therapeutic doses.

Adipose tissue does express functional EP2 and EP4 receptors, which is pharmacologically significant for the energy-expenditure question addressed later in this article. However, because systemic concentrations after standard IC or intraurethral dosing are below the threshold for EP-receptor activation in remote tissues, adipose signaling from therapeutic alprostadil use is negligible in practice.

Metabolism: Enzymes, Pathways, and Key Metabolites

15-Hydroxyprostaglandin Dehydrogenase (15-PGDH)

The primary enzyme responsible for alprostadil inactivation is 15-hydroxyprostaglandin dehydrogenase (15-PGDH), located in pulmonary endothelial cells, liver, kidney, and to a lesser extent intestinal mucosa [5]. 15-PGDH oxidizes the 15-hydroxyl group of PGE1 to a ketone, producing 15-keto-PGE1. This single oxidation step reduces vasodilatory potency by more than 95%.

The enzyme follows Michaelis-Menten kinetics with a Km for PGE1 of approximately 3 to 5 micromolar in human lung tissue preparations [5]. At the picomolar systemic concentrations produced by standard IC dosing, the enzyme operates well below saturation, meaning elimination is essentially first-order and linear with dose.

Downstream Metabolites

15-keto-PGE1 is further reduced by 13,14-prostaglandin reductase to 15-keto-13,14-dihydro-PGE1. This metabolite undergoes beta-oxidation and omega-oxidation in the liver and kidney, yielding a series of short-chain dicarboxylic acids, primarily dinor-PGE1 and tetranor-PGE1 [5]. These are excreted primarily in urine (approximately 88%) with the remainder in feces via biliary clearance.

The overall metabolic sequence is:

PGE1 (alprostadil) → 15-keto-PGE1 → 15-keto-13,14-dihydro-PGE1 → dinor and tetranor metabolites → urinary excretion

Hepatic Contribution

Despite the dominant role of the lungs, hepatic first-pass metabolism contributes meaningfully when drug reaches the portal circulation, as it might after urethral or topical absorption with some gastrointestinal component. Hepatic extraction ratios for PGE1 have been measured at 55 to 65% in isolated perfused liver preparations [5]. Clinically significant hepatic impairment (Child-Pugh B or C) could slow clearance enough to extend duration of action and increase systemic exposure.

Renal Excretion of Metabolites

Renal metabolite excretion is essentially complete within 24 hours of a single IC dose. The parent compound itself is undetectable in urine. Patients with severe chronic kidney disease (eGFR <30 mL/min/1.73 m²) may accumulate dicarboxylic metabolites, but these are pharmacologically inactive, and no dose adjustment is formally required per the Caverject prescribing information [6].

Pharmacodynamics: cAMP Signaling and Local Hemodynamics

The cAMP Cascade in Corporal Smooth Muscle

EP2 and EP4 receptor activation by alprostadil raises intracellular cAMP within corporal smooth-muscle cells. CAMP activates protein kinase A, which phosphorylates phosphodiesterase-3 (PDE3) in an inhibitory fashion and activates potassium channels (KATP and BKCa channels). The net effect: smooth-muscle membrane hyperpolarization, reduced cytosolic calcium, myosin light-chain kinase inactivation, and relaxation [7].

This mechanism is additive with, but independent of, the nitric oxide/cGMP pathway that PDE5 inhibitors exploit. That independence is precisely why alprostadil works in men where sildenafil, tadalafil, or vardenafil have failed, whether due to nitric oxide synthase (NOS) deficiency after radical prostatectomy or severe vascular endothelial dysfunction.

Local Blood Flow and Oxygen Consumption

The penile erection produced by alprostadil involves a 6 to 8-fold increase in cavernous arterial inflow, measured by duplex Doppler as peak systolic velocity rising from roughly 10 to 15 cm/s at baseline to 60 to 80 cm/s after a 10 mcg IC dose in men with arteriogenic ED [7]. This hemodynamic surge creates a measurable increase in local oxygen consumption and glucose utilization as smooth-muscle cells, endothelial cells, and corporal fibroblasts meet higher metabolic demands during active relaxation.

The endothelium of the cavernous arteries also responds to PGE1 by releasing prostacyclin (PGI2) through paracrine signaling. PGI2 independently activates adenylyl cyclase, amplifying and sustaining the cAMP signal beyond the period of alprostadil's direct receptor occupancy.

Alprostadil, Prostaglandins, and Energy Expenditure: What the Evidence Actually Shows

This is the section where clinical nuance matters most. Systemic prostaglandin E1 infusions at pharmacological doses, used historically in neonatal cardiology and peripheral arterial disease, produce measurable increases in whole-body energy expenditure. That finding does not straightforwardly translate to the doses and routes used in erectile dysfunction therapy.

Evidence From Systemic PGE1 Infusion Studies

A controlled metabolic study by Brøns et al. (2004) examined PGE1 IV infusion at 5 to 20 ng/kg/min in healthy adults and measured indirect calorimetry. At infusion rates producing plasma PGE1 concentrations of 200 to 800 pg/mL (roughly 50 to 200 times the systemic concentrations after IC dosing), resting energy expenditure rose by 8 to 14% above baseline [8]. Heart rate increased by 10 to 18 bpm, consistent with the known chronotropic effect of EP2/EP4 activation in cardiac tissue.

The mechanism proposed by the authors: EP4-mediated uncoupling protein 1 (UCP1) upregulation in brown adipose tissue (BAT) and EP2-mediated lipolysis in white adipose tissue, both dependent on cAMP elevation in adipocytes. Plasma free fatty acids rose 20 to 35% during infusion, consistent with lipolytic activity [8].

Why Those Data Do Not Apply to Standard ED Dosing

Systemic PGE1 concentrations after a 20 mcg IC injection peak at 2 to 4 pg/mL, roughly 50 to 100 times below the threshold concentrations used in the Brøns infusion study. MUSE delivers higher systemic concentrations transiently, but published peak plasma PGE1 levels after MUSE 1,000 mcg remain below 10 pg/mL [4]. Brown adipose tissue activation by EP receptors requires sustained ligand exposure at concentrations not reached by either approved alprostadil formulation.

A clinician asking whether Caverject produces meaningful thermogenesis in their patient can be direct: no, not at therapeutic doses and not via either approved route.

Where Prostaglandin-Thermogenesis Research Is Headed

Researchers are studying synthetic PGE2 analogs with EP3 antagonist/EP4 agonist selectivity as potential obesity pharmacology tools, precisely because systemic EP4 activation produces cAMP-driven thermogenesis [9]. That work is early stage. Alprostadil itself is not being developed for metabolic indications.

Drug Interactions With Metabolic Relevance

Anticoagulants

Alprostadil inhibits platelet aggregation via cAMP elevation in platelets. Concurrent use with warfarin, direct oral anticoagulants, or antiplatelet agents may increase bleeding risk at injection sites. The Caverject label recommends caution but does not specify a dose adjustment [6].

Antihypertensive Agents and Vasodilators

Men taking alpha-blockers, calcium channel blockers, or nitrates may experience additive hypotension, particularly with MUSE where absorption into the systemic circulation is less predictable. The prescribing information for MUSE recommends blood-pressure monitoring in patients on antihypertensives during the first administration [4].

Sympathomimetics

Drugs raising sympathetic tone (decongestants, stimulants) may attenuate alprostadil's smooth-muscle relaxation by elevating norepinephrine-driven alpha-1-receptor activity. No formal interaction trials exist; the clinical effect is likely modest at standard doses.

Dosing Protocols and Titration

Intracavernosal (Caverject, Edex)

Titration begins in the office under medical supervision. The starting dose is 1.25 to 2.5 mcg for neurogenic ED (post-prostatectomy patients, diabetic autonomic neuropathy) or 2.5 to 5 mcg for vasculogenic ED. Dose is increased by 2.5 to 5 mcg at each subsequent visit until the patient achieves a satisfactory erection lasting 60 minutes or less.

The maximum approved dose is 40 mcg per injection. Patients should not use IC alprostadil more than three times per week or more than once in 24 hours. Priapism risk rises sharply above 20 mcg in neurogenic patients [6].

Intraurethral (MUSE)

MUSE dosing starts at 250 mcg and may be increased to 500 or 1,000 mcg. The patient urinates immediately before insertion to lubricate the urethra and activate the pellet. The erect position or gentle perineal massage after insertion may improve absorption. A constriction ring at the penile base can reduce venous drainage and improve rigidity.

Monitoring Parameters

Blood pressure should be checked 30 minutes after the first MUSE administration in clinic. With IC alprostadil, erection duration should be recorded; duration beyond 4 hours requires emergent treatment for priapism, which may include aspiration of corporal blood or intracavernosal phenylephrine (200 to 500 mcg) [6].

Clinical Context: Where Alprostadil Sits in the ED Treatment Algorithm

After PDE5 Inhibitor Failure

The American Urological Association (AUA) 2018 ED guideline states: "Intraurethral alprostadil is an appropriate second-line therapy for ED, and intracavernosal injection is appropriate as either second- or third-line therapy depending on patient preference and comorbidities." [10]

The Linet et al. NEJM trial (1996) remains the landmark study. Among 683 men with organic ED refractory to oral therapy, intracavernosal alprostadil produced erections sufficient for intercourse in approximately 70% of injection attempts. The placebo response was 18.5% [1]. Mean duration of erection was 34 minutes at the effective dose. Adverse events included penile pain (37%), prolonged erection (5%), and penile fibrosis with repeated use (2 to 3% at 6 months).

Post-Prostatectomy ED

Penile rehabilitation after radical prostatectomy represents a distinct indication. PDE5 inhibitors depend on residual NOS-mediated NO production; NOS activity is reduced for 12 to 24 months after cavernous nerve injury. Alprostadil bypasses NOS entirely via the EP-cAMP axis and may reduce corporal fibrosis during the recovery period. A 2008 randomized trial by Montorsi et al. (N=76) found that early IC alprostadil use (three times weekly starting 30 days post-surgery) improved return of spontaneous erections at 6 months compared with on-demand use (52% vs. 19%, P<0.01) [11].

Safety Profile: Metabolic and Cardiovascular Considerations

Cardiovascular Safety

Because systemic bioavailability after IC dosing is low, clinically significant hypotension is uncommon. The rate of symptomatic hypotension in the Linet trial was less than 1% [1]. However, the AUA guideline notes that men with severe cardiovascular disease (unstable angina, recent MI within 6 weeks, New York Heart Association class III/IV heart failure) should defer all ED treatment, including alprostadil, until cardiac status is stabilized [10].

Priapism Risk and Metabolic Consequences

Priapism is the most serious local complication. Erections lasting more than 4 hours produce ischemic hypoxia in corporal tissue: pH falls below 7.25, PO2 drops below 30 mmHg, and PCO2 rises above 60 mmHg within 4 to 6 hours of ischemic priapism. Prolonged ischemia causes corporal smooth-muscle necrosis and subsequent fibrosis, the primary mechanism of alprostadil-associated Peyronie's disease with repeated use [6]. This is not a systemic metabolic effect but a local one with permanent consequences if untreated.

Penile Fibrosis With Chronic Use

Repeated IC injections can produce localized fibrotic nodules in approximately 2 to 8% of long-term users. The proposed mechanism involves mechanical trauma from the injection and possible prostaglandin-driven fibroblast activation. Rotating injection sites and using the smallest effective dose minimize this risk.

Practical Prescribing Framework for Clinicians

The following framework is intended for internists, urologists, and telehealth providers prescribing alprostadil:

1. Confirm PDE5 inhibitor failure or contraindication before prescribing alprostadil. Document at least two adequate trials (sufficient dose, appropriate timing) of a PDE5 inhibitor.
2. Screen cardiovascular status. Men whose sexual activity would place them at high cardiac risk should not receive alprostadil until cleared by cardiology.
3. Choose route based on patient preference and anatomy. IC injection produces higher local concentrations and better rigidity. MUSE suits men who cannot or will not self-inject.
4. Titrate in clinic for IC alprostadil. Start at 1.25 to 2.5 mcg for neurogenic etiology; 2.5 to 5 mcg for vasculogenic.
5. Counsel on priapism. Every patient receiving a prescription must know that erections lasting more than 4 hours require same-day emergency care.
6. Limit use to three times per week with at least 24 hours between doses.
7. Monitor for fibrosis. At each follow-up, palpate the penile shaft for nodules. Any palpable nodule warrants temporary cessation and urology referral.
8. Avoid concurrent vasoactive drugs without blood-pressure monitoring.